Program
ORMD-0801
Also written as “ORMD-0801 8 mg”, “ORMD-0801 16 mg” and “ORMD-0801 (Insulin) capsule 8 mg BD”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Oramed.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Oramed | 81 open or running | phase 3since Feb 8, 2021 | Mar 20, 2014 | Apr 25, 2027phase 3 · NCT06731075 |
Also a collaborator on its studies: integrium.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 20, 2014First study: phase 2 study in Diabetes Mellitus, Type 1First studyNCT02094534 · 25 enrolled · United States
- Jul 8, 2015Phase 2 study in Diabetes Mellitus, Type 2NCT02496000 · 188 enrolled · United States
- Oct 13, 2016Phase 2 study in Diabetes Mellitus, Type 2NCT02954601 · 31 enrolled · United States
- Mar 1, 2018Phase 2 study in Diabetes Mellitus, Type 2NCT03467932 · 373 enrolled · United States
- Sep 21, 2020Phase 2 study in Diabetes Mellitus, Type 2NCT04564846 · 49 enrolled · United States
- Nov 1, 2020Phase 2 study in Diabetes Mellitus, Type 2NCT04618744 · 32 enrolled · United States, Israel
- Feb 8, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04754334 · 346 enrolled · United States
- Dec 9, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06731075 · 300 planned · United States
Ahead
- Apr 25, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT06731075
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06731075Diabetes Mellitus, Type 2 · United States | 3 | Not yet recruiting | Apr 25, 2027 | 300 |
| NCT04754334Diabetes Mellitus, Type 2 · United States | 3 | Terminated | Jan 13, 2023 | 346 |
| NCT04618744Diabetes Mellitus, Type 2 · United States, Israel | 2 | Completed | Jun 27, 2022 | 32 |
| NCT04564846Diabetes Mellitus, Type 2 · United States | 2 | Completed | Jun 7, 2022 | 49 |
| NCT03467932Diabetes Mellitus, Type 2 · United States | 2 | Completed | Oct 21, 2019 | 373 |
| NCT02954601Diabetes Mellitus, Type 2 · United States | 2 | Completed | Feb 24, 2017 | 31 |
| NCT02496000Diabetes Mellitus, Type 2 · United States | 2 | Completed | Jun 27, 2016 | 188 |
| NCT02094534Diabetes Mellitus, Type 1 · United States | 2 | Completed | Aug 2014 | 25 |
How it is read
Names in the registry
- “ORMD-0801”, 3 entries
- “ORMD-0801 8 mg”, 1 entry
- “ORMD-0801 16 mg”, 1 entry
- “ORMD-0801 (Insulin) capsule 8 mg BD”, 1 entry
- “Cohort A: ORMD-0801”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 7 studies
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.